RxDoctor Payments Data

Y Pham, MD

Internal Medicine · Marshall, TXNPI 1538161567

Payments from drug & device makers

$2,257in general payments, 2019–2025

Across 159 payments — averaging $14.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$375
  • Amgen$255
  • Novo Nordisk$224
  • Pfizer$177
  • GSK$158
  • AbbVie$147
  • plus $922 from 15 others

What the payments were for

  • Food & beverage$2,24499%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,257 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$101,722
Medicare patients
428
Services billed
1,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide177$227,796
MounjaroTirzepatide165$219,040
EliquisApixaban215$201,334
XareltoRivaroxaban104$115,810
JardianceEmpagliflozin115$102,286
Trelegy ElliptaFluticasone/Umeclidin/Vilanter94$97,413
TrulicityDulaglutide72$94,011
JanuviaSitagliptin Phosphate82$84,435
LinzessLinaclotide57$44,826
FarxigaDapagliflozin Propanediol40$37,985
EntrestoSacubitril/Valsartan26$33,732
Synjardy XrEmpagliflozin/Metformin Hcl24$24,723
Breo ElliptaFluticasone/Vilanterol26$23,183
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen735$21,437
WegovySemaglutide16$19,552

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$138$313,051237 claims
Novo NordiskOzempic, Wegovy$224$247,348193 claims
PfizerEliquis, Premarin$177$207,498227 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Combivent Respimat, Spiriva Respimat$65$181,618199 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$158$130,586148 claims
Johnson & JohnsonXarelto$34$115,810104 claims
AstraZenecaFarxiga, Symbicort$375$52,32781 claims
AbbVieLinzess$147$44,82657 claims
NovartisEntresto$93$33,73226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Marshall

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →